Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andre T Baron

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Nature Clinical Practice. Oncology|November 3, 2005
Nadir CA125 concentration as a prognostic indicator in ovarian cancerAndre T Baron, Nita Maihle
Methods in Molecular Biology (Clifton, N.J.)|June 20, 2006
Soluble epidermal growth factor receptor acridinium-linked immunosorbent assayJacqueline M Lafky, Andre T Baron, Nita J Maihle
Cancer|September 20, 2013
The epidermal growth factor receptor conundrumJason A Wilken, Andre T Baron, Nita J Maihle
Hybridoma and Hybridomics|August 8, 2002
Generation and characterization of polyclonal antibodies specific for human p110 sEGFRTrace A Christensen, Jill L Reiter, Andre T Baron, et al.
Biochimica Et Biophysica Acta|February 23, 2008
Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancerJacqueline M Lafky, Jason A Wilken, Andre T Baron, et al.
Statistics in Medicine|August 5, 2015
Flexible regression models for ROC and risk analysis, with or without a gold standardAdam J Branscum, Wesley O Johnson, Timothy E Hanson, et al.
Idrugs : the Investigational Drugs Journal|May 12, 2009
Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancerAndre T Baron, Jason A Wilken, Daniel E Haggstrom, et al.
Biochemistry|April 16, 2011
Identification of immunoreactive regions of homology between soluble epidermal growth factor receptor and α5-integrinJason A Wilken, Andre T Baron, Ramsey A Foty, et al.
Cancer Research|March 12, 2009
Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cellsMurli Narayan, Jason A Wilken, Lyndsay N Harris, et al.
Gene Therapy & Molecular Biology|August 19, 2010
Decreased risk of bladder cancer in men treated with quinazoline-based α1-adrenoceptor antagonistsFrances M Martin, Andrew M Harris, Randall G Rowland, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Nature Clinical Practice. Oncology|November 3, 2005
Nadir CA125 concentration as a prognostic indicator in ovarian cancerAndre T Baron, Nita Maihle
Methods in Molecular Biology (Clifton, N.J.)|June 20, 2006
Soluble epidermal growth factor receptor acridinium-linked immunosorbent assayJacqueline M Lafky, Andre T Baron, Nita J Maihle
Cancer|September 20, 2013
The epidermal growth factor receptor conundrumJason A Wilken, Andre T Baron, Nita J Maihle
Hybridoma and Hybridomics|August 8, 2002
Generation and characterization of polyclonal antibodies specific for human p110 sEGFRTrace A Christensen, Jill L Reiter, Andre T Baron, et al.
Biochimica Et Biophysica Acta|February 23, 2008
Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancerJacqueline M Lafky, Jason A Wilken, Andre T Baron, et al.
Statistics in Medicine|August 5, 2015
Flexible regression models for ROC and risk analysis, with or without a gold standardAdam J Branscum, Wesley O Johnson, Timothy E Hanson, et al.
Idrugs : the Investigational Drugs Journal|May 12, 2009
Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancerAndre T Baron, Jason A Wilken, Daniel E Haggstrom, et al.
Biochemistry|April 16, 2011
Identification of immunoreactive regions of homology between soluble epidermal growth factor receptor and α5-integrinJason A Wilken, Andre T Baron, Ramsey A Foty, et al.
Cancer Research|March 12, 2009
Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cellsMurli Narayan, Jason A Wilken, Lyndsay N Harris, et al.
Gene Therapy & Molecular Biology|August 19, 2010
Decreased risk of bladder cancer in men treated with quinazoline-based α1-adrenoceptor antagonistsFrances M Martin, Andrew M Harris, Randall G Rowland, et al.
Pageof 3